Deaths involving MDMA and the concomitant use of pharmaceutical drugs

Journal of Analytical Toxicology

Volumn 35, Issue 4, 2011, Pages 219-226

  Pilgrim, J L ^a   Gerostamoulos, D ^a,b   Drummer, Olaf H ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIAN INSTITUTE OF FORENSIC MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPRAZOLAM; AMPHETAMINE; CITALOPRAM; CODEINE; DIAZEPAM; DOSULEPIN; DOXYLAMINE; DRONABINOL; FLUOXETINE; FLUVOXAMINE; FUROSEMIDE; IBUPROFEN; KETAMINE; METHADONE; METHAMPHETAMINE; METOCLOPRAMIDE; MIRTAZAPINE; MOCLOBEMIDE; MORPHINE; NORDAZEPAM; OLANZAPINE; PARACETAMOL; SERTRALINE; TEMAZEPAM; TRAMADOL; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; AUTOPSY; BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSIVE CRISIS; MALE; SEROTONIN TOXICITY; SUDDEN DEATH; TOXICITY;

EID: 79954579024     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/anatox/35.4.219     Document Type: Article

References (38)

1. United Nations Office on Drugs and Crime (UNODC), V. World Drug Report 2009. http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf.
2. G. Fowler, S. Kinner, and L. Krenske. Containing ecstasy: analytical tools for profiling an illegal drug market. http://espace.library.uq.edu.au/view/UQ:167615.
3. Australian Bureau of Criminal Intelligence (ABCI). Australian Illicit Drug Report 2001-02. http://www.crimecommission.gov.au/publications/iddr/2001_02.htm.
4. H. Kalant. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165(7): 917-928 (2001).
5. J. Copeland, P. Dillon, and M. Gascoigne. Ecstasy and the Concomitant Use of Pharmaceuticals. Technical Report No. 201. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. http://www.med.unsw.edu.au/ndarcweb.nsf/resources/TR_38/$file/TR.201.pdf.
6. E. Silins, J. Copeland, and P. Dillon. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust. N. Z. J. Psychiatry 41: 649-655 (2007).
7. B.C. Kelly. Mediating MDMA-related harm: preloading and postloading among Ecstasy-using youth. J. Psychoactive Drugs 41(1): 19-26 (2009).
8. J. Copeland, P. Dillon, and M. Gascoigne. Ecstasy and the concomitant use of pharmaceuticals. Addict. Behav. 31(2): 367-370 (2006).
9. J. Morton. Ecstasy: pharmacology and neurotoxicity. Curr. Opin. Pharmacol. 5(1): 79-86 (2005).
10. A.G. Montoya, R. Sorrentino, S.E. Lukas, and B.H. Price. Longterm neuropsychiatric consequences of "ecstasy" (MDMA): a review. Harv. Rev. Psychiatry 10(4): 212-220 (2002).
11. J.L. Pilgrim, D. Gerostamoulos, O.H. Drummer, and M. Bollmann. Involvement of amphetamines in sudden and unexpected death. J. Forensic Sci. 54(2): 478-485 (2009).
12. E. Vuori, J.A. Henry, I. Ojanpera, R. Nieminen, T. Savolainen, P. Wahlsten, and M. Jantti. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98(3): 365-368 (2003).
13. M.J. Smilkstein, S.C. Smolinske, and B.H. Rumack. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J. Toxicol. Clin. Toxicol. 25(1-2): 149-159 (1987).
14. A.C. Parrott. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 71(4): 837-844 (2002).
15. P.K. Gillman. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry 59(11): 1046-1051 (2006).
16. J.A. Levisky, D.L. Bowerman, W.W. Jenkins, D.G. Johnson, and S.B. Karch. Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci. Int. 121(3): 157-160 (2001).
17. O.H. Drummer. Post-mortem toxicology. Forensic Sci. Int. 165(2-3): 199-203 (2007).
18. O.H. Drummer, S. Horomidis, S. Kourtis, M.L. Syrjanen, and P. Tippett. Capillary gas chromatographic drug screen for use in forensic toxicology. J. Anal. Toxicol. 18(3): 134-138 (1994).
19. Thomson Reuters (Healthcare). Micromedex® Healthcare Series [Internet database]. 1974-2010.
20. F. Couper and B. Logan. Drugs and Human Performance Fact Sheets. 2004, National Highway Traffic Safety Administration.
21. J.R. Oesterheld, S.C. Armstrong, and K.L. Cozza. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 45(1): 84-87 (2004).
22. G.B. Kaskey. Possible interaction between an MAOI and "ecstasy". Am. J. Psychiatry 149(3): 411-412 (1992).
23. J.L. Pilgrim, D. Gerostamoulos, and O.H. Drummer. Deaths involving serotonergic drugs. Forensic Sci. Int. 198(1-3): 110-117 (2010).
24. A. Freezer, A. Salem, and R.J. Irvine. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and paramethoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res. 1041(1): 48-55 (2005).
25. R. Amrein, W. Hetzel, M. Stabl, and W. Schmid-Burgk. RIMA: a safe concept in the treatment of depression with moclobemide. Can. J. Psychiatry 37(Suppl 1): 7-11 (1992).
26. J.L. Pilgrim, D. Gerostamoulos, N.Woodford, and O.H. Drummer. Serotonin toxicity involving MDMA (Ecstasy) and moclobemide. submitted to Forensic Sci. Int.
27. H. Sternbach. The serotonin syndrome. Am. J. Psychiatry 148: 705-713 (1991).
28. P.D. Mueller and W.S. Korey. Death by "ecstasy": the serotonin syndrome? Ann. Emerg. Med. 32(3 Pt 1): 377-380 (1998).
29. Drugs and Crime Prevention Committee (DCPC) Inquiry into amphetamine and party drug use in Australia 2004-05, 2005.
30. S.Williamson, M. Gossop, B. Powis, P. Griffiths, J. Fountain, and J. Strang. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend. 44(2-3): 87-94 (1997).
31. F.P. Guengerich. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8(1): E101-111 (2006).
32. Anzenbacher, P. and Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci. 8(5-6): 737-747 (2001).
33. M. Dostalek, J. Jurica, J. Pistovcakova, M. Hanesova, J. Tomandl, I. Linhart, I. and A. Sulcova. Effect of methamphetamine on cytochrome P450 activity. Xenobiotica 37(12): 1355-1366 (2007).
34. G. Skopp. Preanalytic aspects in postmortem toxicology. Forensic Sci. Int. 142(2-3): 75-100 (2004).
35. B. Madea and F. Musshoff. Postmortem toxicology. Forensic Sci. Int. 142(2-3): 71-73 (2004).
36. A. Koski. Interpretation of postmortem toxicology results: pharmacogenetics and drug-alcohol interaction. Dissertation, University of Helsinki, Helsinki, Finland, 2005.
37. O.H. Drummer. Postmortem toxicology of drugs of abuse. Forensic Sci. Int. 142(2-3): 101-113 (2004).
38. S.L. Treiser, C.S. Cascio, T.L. O'Donohue, N.B. Thoa, D.M. Jacobowitz, and K.J. Kellar. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science 213(4515): 1529-1531 (1981).